Research map: The first domestic combination of nurulimab + prolgolimab: from clinical development and economic analysis to real-world use in disseminated melanoma

Back to the article

Papers in this map

  1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma · Jedd D. Wolchok · 2017 · 5454 citations · Cited by this paper
  2. Frequency of polymorphic variants of the IFNG (rs2069705) and IL28b (rs12979860) genes depending on the severity of clinical manifestations of Opisthorchis felineus invasion · 2026 · Related
  3. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma · James Larkin · 2019 · 3789 citations · Cited by this paper
  4. Late therapeutic use of tauractant in infants with bronchopulmonary dysplasia: A retrospective comparative study · 2026 · Related
  5. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma · Caroline Robert · 2019 · 1419 citations · Cited by this paper
  6. Clinical significance of hyperammonemia in non-alcoholic fatty liver disease · 2026 · Related
  7. Recent Advances in the Treatment of Melanoma · Brendan D. Curti · 2021 · 397 citations · Cited by this paper
  8. Changes in results of a skin test with recombinant TB allergen during preventive chemotherapy in children exposed to TB cases · 2026 · Related
  9. Immunotherapy in Melanoma: Recent Advances and Future Directions · Andrew Knight · 2023 · 258 citations · Cited by this paper
  10. Expiratory disproportion index as an additional parameter of clinical assessment in bilateral laryngeal paralysis · 2026 · Related
  11. Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action · Zena N. Willsmore · 2021 · 203 citations · Cited by this paper
  12. Intestinal endometriosis: Current aspects of pathogenesis, clinical picture, and differential diagnosis (a review of foreign literature) · 2026 · Related
  13. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 · Susan M. Swetter · 2024 · 158 citations · Cited by this paper
  14. Neurological comorbidities in psoriasis and psoriatic arthritis: Neuropathic pain, cognitive impairment and cerebrovascular risk · 2026 · Related
  15. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis · Flora A. Mulkey · 2020 · 83 citations · Cited by this paper
  16. Combined therapy for infectious and inflammatory diseases of the upper respiratory tract (clinical observation) · 2026 · Related
  17. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice · Sergey A. Tjulandin · 2021 · 66 citations · Cited by this paper
  18. Efficacy of rebamipide in Helicobacter pylori eradication regimens: A review of recent experimental and clinical data · 2026 · Related
  19. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis · Andrea Boutros · 2023 · 41 citations · Cited by this paper
  20. Enterosorbents in the combination therapy of alcohol withdrawal syndrome · 2026 · Related
  21. Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review · Yusuke Muto · 2025 · 14 citations · Cited by this paper
  22. Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study · Игорь Вячеславович Самойленко · 2023 · 7 citations · Cited by this paper
  23. IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE · Yekaterina Anokhina · 2018 · 5 citations · Cited by this paper
  24. A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT) · Лев Вадимович Демидов · 2024 · 5 citations · Cited by this paper
  25. Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial · Лев Вадимович Демидов · 2025 · 4 citations · Cited by this paper
  26. Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial · Лев Вадимович Демидов · 2025 · 4 citations · Cited by this paper
  27. Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab · Aleksandr Gordeev · 2024 · 3 citations · Cited by this paper
  28. Modern combined targeted and immunotherapy of metastatic skin melanoma · Светлана Проценко · 2020 · 2 citations · Cited by this paper
  29. A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma. · Fedor Kryukov · 2024 · 2 citations · Cited by this paper
  30. Comparative efficacy and safety of prolgolimab + nurulimab and nivolumab + ipilimumab in the first-line therapy of metastatic or unresectable melanoma: A systematic review and matching-adjusted indirect comparison · А. А. Феденко · 2025 · 2 citations · Cited by this paper
  31. Cost-effectiveness analysis of nurulimab and prolgolimab combination used in adult patients with unresectable or metastatic cutaneous melanoma · S. К. Zyryanov · 2026 · 1 citation · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper

Source: OpenAlex (CC0)